Tagged with AZ

China The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment news on Clover Biopharmaceuticals, Sciwind Biosciences, and Gensciences.   AstraZeneca signs deal with Chinese biotech Junshi Biosciences to market anti-PD-1 cancer drug in China https://www.biopharma-reporter.com/Article/2021/03/01/AstraZeneca-betting-on-China-s-PD-1-cancer-market AstraZeneca has signed a…

Brazil The Brazilian pharma market outperformed the Latin American average in Q1 of 2020 with a growth of 8.2 percent in real terms (inflation adjusted), according to IQVIA. Its size reached USD 21.8 billion, with almost two thirds coming from retail. The overall LatAm pharma market grew 6 percent in average…

Americas The latest news from pharma and healthcare in Latin America, including funding and logistics challenges in national COVID-19 vaccination programs, a new variant of the virus in Colombia, and the impasse between Pfizer and the Peruvian government.   First Covid-19 Vaccines Are Given in Latin America, But Region Faces Challenges…

Brazil Six of the top ten companies in the Brazilian pharma market are domestic.* Read on for an introduction to some of the Brazilian giants that are perhaps less well known internationally but play a leading role in what is the world’s sixth largest pharma market, serving a patient population of…

Roundup The latest from healthcare and the life sciences in Latin America, including the most recent wave of Indian pharma investment; Argentina’s ongoing struggle with COVID-19; issues around unchecked use of an anti-parasite drug; and the seismic economic and social impact of upcoming cannabis legalisation in Mexico.   Six Indian drug…

News Roundup The latest from the fight against COVID-19 in Latin America, including J&J’s vaccine trials, issues surrounding Chinese-made diagnostic tests, Colombia’s vaccine manufacturing capacity, and potential compulsory licensing in Brazil.   COVID-19 vaccine: J&J seeks 20,000 trial volunteers in Latin America, one-third of planned global total https://www.businesstoday.in/sectors/pharma/COVID-19-vaccine-jj-seeks-20000-trial-volunteers-in-latin-america/story/415224.html Josue Bacaltchuk, vice president…

China Since the Chinese government unrolled an unprecedented volume-based procurement initiative for essential drugs used in the public hospital system in November 2018 in a bid to curb unsustainable healthcare expenditures, domestic and foreign drug manufacturers have been forced into an increasingly cutthroat race to the bottom, at least for the…

Roundup A selection of the latest stories from Latin American pharma, including AstraZeneca’s new COVID-19 vaccine production agreements in Mexico and Argentina, human trial approvals for other COVID-19 vaccines in Brazil, and US firm Catalent’s scale up of its Argentinian manufacturing footprint.   AstraZeneca will work with Mexico, Argentina to produce…

Brazil Panorama Faramceutico’s editorial team look at how the ongoing COVID-19 pandemic stands to affect Brazil’s over the counter (OTC) market segment during and after the COVID-19 pandemic.*   The OTC segment represents more than 40 percent of the self-service market in pharmacies. As it covers items with exclusive sale in…

Brazil In the race to develop the world’s first COVID-19 vaccine, Brazil – now one of the world’s worst-affected countries – is becoming an attractive clinical trial destination for biopharma companies that heading into phase III trials. Chinese firm Sinovac recently received regulatory approval to test its vaccine candidate in Brazil…

Roundup In recent pharma news from around Latin America, countries are beginning to manufacture their own tests and equipment for dealing with the COVID-19 pandemic so as to reduce dependence on outside sources. Moreover, as vaccines begin being developed globally, pharma firms are looking to Latin America to test their efficacy.…

Brazil The editorial team at Panorama Farmaceutico explain how the COVID-19 pandemic and global trade flow stoppages are impacting the manufacture and supply of medicines within Brazil.*   The COVID-19 pandemic has again brought to the fore Brazil’s need to reduce its dependence on active pharmaceutical ingredients (APIs) from abroad. Brazil imports…